Published in Medical Letter on the CDC and FDA, October 30th, 2005
Remicade is now indicated for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy.
"The approval of Remicade for the treatment of UC represents a major breakthrough for patients suffering from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA